ArticleGland surgery2026
Complete excision of the nipple core combined with inverted nipple correction: a novel surgical intervention for reducing recurrence in Zuska's disease.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Zuska's disease, a rare chronic inflammatory condition of the subareolar breast tissue, is characterized by recurrent non-puerperal abscesses and lactiferous duct fistulas. This condition poses significant therapeutic challenges because of its high recurrence rates. This study aimed to assess the effectiveness of a novel surgical approach integrating complete nipple core excision and inverted nipple correction in decreasing recurrence rates among patients with Zuska's disease, in comparison with conventional treatments. Methods: A retrospective analysis was performed on 109 patients diagnosed with Zuska's disease at the Maternal and Child Health Hospital of Hubei Province from January 2008 to December 2022. The inclusion criteria were non-lactating females with nipple inversion, pathological verification of squamous metaplasia, and comprehensive follow-up data. All patients underwent an arcuate periareolar incision, complete excision of subareolar ducts, correction of nipple inversion through purse-string suturing, and postoperative administration of bromocriptine for hyperprolactinemia. Follow-up evaluations encompassed wound healing, correction of nipple inversion, and recurrence at 1, 6, 12, 24, and 36 months. Results: The median age of the patients was 23 years (range: 13-54 years), and there were 79 nulliparous females. The mean duration of the surgery was 42±15 minutes, accompanied by blood loss (8.7±3.6 mL). No postoperative infections were detected. At a median follow-up period of 24 months (range: 18-36 months), only one case of recurrence (1%) was observed. In patients with a history of prior surgeries (33/109), the preoperative recurrence rates were significantly decreased after the surgery. In 94% of the patients, the cosmetic outcomes were evaluated as excellent/good (73 patients scored 91-100; 29 patients scored 80-90). Postoperative bromocriptine therapy normalized the prolactin levels in 37 patients with hyperprolactinemia. Conclusions: This comprehensive surgical approach effectively resolves ductal epithelial hyperplasia and anatomical malformations, attaining a 99% disease-free survival rate. In comparison with traditional methods, it yields superior aesthetic outcomes. The low recurrence rate and negligible complications substantiate its implementation as a standard treatment for Zuska's disease. Additional multicenter trials are necessary to verify the long-term efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.